close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

133.80 -2.46 (-1.81%)
Delayed Quote Updated: 2:42 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
MIMRYLO™ (rusfertide) Approved by FDA for the Treatment of Erythrocytosis in Adults with Polycythemia Vera; Approval Triggered $275 Million in Payments to Protagonist Comprehensive Phase 2b Program... 
From Protagonist Therapeutics
Via ACCESS Newswire
Protagonist Therapeutics (NASDAQ:PTGX) Eyes Breakout as High Growth Momentum Builds ↗
Via Chartmill
News headline image
Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026
From Protagonist Therapeutics
Via ACCESS Newswire
Protagonist Therapeutics (NASDAQ:PTGX): Strong Growth Meets Constructive Technical Setup ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX): High Growth Momentum Meets Breakout Setup ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth With a High-Quality Technical Setup ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Combines High Growth Momentum With a Breakout Setup ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth with a Promising Technical Setup ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Passes Minervini Trend Template and High-Growth Screen ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX): A High Growth Momentum Stock Meeting the Mark Minervini Technical Setup ↗
Via Chartmill
News headline image
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment ↗
Protagonist Therapeutics (NASDAQ:PTGX) said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia... 
Via MarketBeat
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
One of J&J's investments stands head-and-shoulders above the rest. 
Via The Motley Fool
Protagonist Therapeutics (NASDAQ:PTGX) Shows Technical Strength and High Growth Momentum ↗
Via Chartmill
News headline image
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
Via ACCESS Newswire
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology. 
Via The Motley Fool
News headline image
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
Via ACCESS Newswire
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases. 
Via The Motley Fool
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.